Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. is involved in the research, development, production, and sales of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 (rhBMP-2) bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; and Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia. Additionally, the company provides Jitansu, a fosaprepitant dimeglumine injection for chemotherapy-induced nausea and vomiting; Jifuwei, a fulvestrant injection for advanced breast cancer; Yinuojia, an enoxaparin sodium injection for venous thromboembolic diseases; Jipailin, a low molecular weight heparin sodium injection for venous thromboembolic diseases; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by radiation therapy, chemotherapy, or postoperative conditions. It offers its products in the fields of orthopedics, metabolic diseases, oncology, and hematology. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.